International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 49
  • Journal CiteScore: 11.20
  • Journal Impact Factor: 8.24
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page


A comparative study of Sulbactomax versus Ceftriaxone and betalactamase inhibitor and their effect on mutant prevention in ESBL producing organisms

Anurag Payasi, Shailesh Kumar, Manu Chaudhary

Objective: In the present investigation, MPC of Sulbactomax was compared with ceftriaxone+sulbactam and ceftriaxone against ESBL producing Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, Proteus vulgaris, Escherichia coli and Citrobacter braakii. Methods:The MPC of each antibacterial agent was determined using agar dilution method with a final inoculum size of 1010 CFU/ml of each organism. Result: The Sulbactomax MPC for ESBL organisms was in the range from 32 to 128 μg/ml and for ceftriaxone+sulbactam and ceftriaxone, it ranged from >256 and >512, respectively. The results suggest that Sulbactomax is highly efficacious in-vitro against selected ESBL producing organisms with lower MPC values, when compared with the ceftriaxone+sulbactam and ceftriaxone. Conclusion: Sulbactomax is one of the best choice to treat the infections caused by the above said ESBL producing micro-organisms, indicating to be effective in the prevention of disease caused by these ESBL organisms.